Literature DB >> 21638273

GATA-3 up-regulation in CD8+ T cells as a biomarker of immune dysfunction in systemic sclerosis, resulting in excessive interleukin-13 production.

Thomas A Medsger1, Dana E Ivanco, Lela Kardava, Penelope A Morel, Mary R Lucas, Patrizia Fuschiotti.   

Abstract

OBJECTIVE: Despite the importance of interleukin-13 (IL-13) in systemic sclerosis (SSc) and other fibrotic diseases, its mechanisms of action are not understood. We have reported that excessive amounts of IL-13 are produced by peripheral blood effector CD8+ T cells from patients with diffuse cutaneous SSc (dcSSc). The aim of the present study was to establish the molecular basis of IL-13 dysregulation in the pathogenesis of SSc.
METHODS: Quantitative polymerase chain reaction analysis and intracellular staining were used to study the transcription factors that control naive peripheral blood CD8+ T cell differentiation into type 1 and type 2 cytokine-secreting cells. Intracellular staining revealed that GATA-3 levels in freshly isolated naive CD8+ T cells correlated with specific clinical manifestations. We therefore assessed the effects of GATA-3 inhibition on IL-13 production in CD8+ T cells from the SSc patients.
RESULTS: Freshly isolated naive peripheral blood CD8+ T cells expressed high levels of GATA-3 and failed to down-regulate IL-13 production when cultured under type 1-skewing conditions, but maintained adequate levels of interferon-γ production. Cellular GATA-3 levels were significantly higher in patients with dcSSc and early inflammatory disease. Silencing of GATA-3 with small interfering RNA significantly reduced IL-13 production by CD8+ T cells, demonstrating a causal relationship between GATA-3 and IL-13.
CONCLUSION: These results provide important new insights into SSc pathogenesis and suggest that increased GATA-3 expression in CD8+ T cells could be a highly relevant biomarker of immune dysfunction in patients with dcSSc. GATA-3 could be a novel therapeutic target for this currently incurable disease.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21638273     DOI: 10.1002/art.30489

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  28 in total

1.  Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.

Authors:  Hiroshi Kato; Andras Perl
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

Review 2.  The role of the acquired immune response in systemic sclerosis.

Authors:  Carlo Chizzolini; Francesco Boin
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

3.  Insufficient interleukin-12 signalling favours differentiation of human CD4(+) and CD8(+) T cells into GATA-3(+) and GATA-3(+) T-bet(+) subsets in humanized mice.

Authors:  Eva Billerbeck; Rachael N Labitt; Kevin Vega; Natalia Frias-Staheli; Marcus Dorner; Jing W Xiao; Charles M Rice; Alexander Ploss
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

Review 4.  Role of anti-inflammatory cytokines IL-4 and IL-13 in systemic sclerosis.

Authors:  Xiao-Lei Huang; Yu-Jie Wang; Jun-Wei Yan; Ya-Nan Wan; Bing Chen; Bao-Zhu Li; Guo-Jun Yang; Jing Wang
Journal:  Inflamm Res       Date:  2015-03-01       Impact factor: 4.575

5.  Skin-Resident Effector Memory CD8+CD28- T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis.

Authors:  Gang Li; Adriana T Larregina; Robyn T Domsic; Donna B Stolz; Thomas A Medsger; Robert Lafyatis; Patrizia Fuschiotti
Journal:  J Invest Dermatol       Date:  2016-12-22       Impact factor: 8.551

6.  Reply to Vicetti Miguel et al., "Setting Sights on Chlamydia Immunity's Central Paradigm: Can We Hit a Moving Target?"

Authors:  Raymond M Johnson; Robert C Brunham
Journal:  Infect Immun       Date:  2017-06-20       Impact factor: 3.441

7.  CD8+ T cells in systemic sclerosis.

Authors:  Patrizia Fuschiotti
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

Review 8.  The immune pathogenesis of scleroderma: context is everything.

Authors:  Matthew B Greenblatt; Antonios O Aliprantis
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

9.  Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis.

Authors:  Patrizia Fuschiotti; Adriana T Larregina; Johnan Ho; Carol Feghali-Bostwick; Thomas A Medsger
Journal:  Arthritis Rheum       Date:  2013-01

10.  14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in TC2 and CD8+ lymphocytes from patients with scleroderma.

Authors:  Sandra Cascio; Thomas A Medsger; William F Hawse; Simon C Watkins; Christine Milcarek; Larry W Moreland; Robert A Lafyatis; Patrizia Fuschiotti
Journal:  J Allergy Clin Immunol       Date:  2017-11-15       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.